Next Article in Journal
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition
Next Article in Special Issue
The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?
Previous Article in Journal
Hybrid Clustered Nanoparticles for Chemo-Antibacterial Combinatorial Cancer Therapy
Previous Article in Special Issue
Current Status of Gene Therapy in Hepatocellular Carcinoma
Open AccessReview

Glypican 3-Targeted Therapy in Hepatocellular Carcinoma

Section of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan
Division of Gastrointestinal, Endocrine and Pediatric Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan
Author to whom correspondence should be addressed.
Cancers 2019, 11(9), 1339;
Received: 30 July 2019 / Revised: 3 September 2019 / Accepted: 7 September 2019 / Published: 10 September 2019
(This article belongs to the Special Issue Hepatocellular Cancer Treatment)
Glypican-3 (GPC3) is an oncofetal glycoprotein attached to the cell membrane by a glycophosphatidylinositol anchor. GPC3 is overexpressed in some kinds of tumors, particularly hepatocellular carcinoma (HCC). The prognostic significance of serum GPC3 levels and GPC3 immunoreactivity in tumor cells has been defined in patients with HCC. In addition to its usefulness as a biomarker, GPC3 has attracted attention as a novel therapeutic target molecule, and clinical trials targeting GPC3 are in progress. The major mechanism of anti-GPC3 antibody (GPC3Ab) against cancer cells is antibody-dependent cellular cytotoxicity and/or complement-dependent cytotoxicity. Since GPC3Ab is associated with immune responses, a combination of protocols with immune checkpoint inhibitors has also been investigated. Moreover, some innovative approaches for GPC3-targeting therapy have emerged in recent years. This review introduces the results of recent clinical trials targeting GPC3 in HCC and summarizes the latest knowledge regarding the role of GPC3 in HCC progression and clinical application targeting GPC3. View Full-Text
Keywords: hepatocellular carcinoma; glypican-3; codrituzumab; T cell-redirecting antibody; CAR-T hepatocellular carcinoma; glypican-3; codrituzumab; T cell-redirecting antibody; CAR-T
Show Figures

Figure 1

MDPI and ACS Style

Nishida, T.; Kataoka, H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers 2019, 11, 1339.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop